Ethacizine
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| Trade names | Ethacizin |
| AHFS/Drugs.com | International Drug Names |
| ATC code | C01BC09 (WHO) |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | ~40% (oral)[1] |
| Protein binding | 90% |
| Metabolism | Extensive hepatic |
| Biological half-life | 2.5 hours |
| Identifiers | |
|
|
| CAS Number | 33414-33-4  |
| PubChem (CID) | 107841 |
| ChemSpider | 96982 |
| UNII | FE5SPV1Z6G |
| ChEMBL | CHEMBL1997663  |
| Chemical and physical data | |
| Formula | C22H27N3O3S |
| Molar mass | 413.54 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Ethacizine (ethacyzine) is a class Ic antiarrhythmic agent, related to moracizine. It is used in Russia and some other CIS countries for the treatment of severe and/or refractory ventricular and supraventricular arrhythmias, especially those accompanied by organic heart disease. It is also indicated as a treatment of refractory tachycardia associated with Wolff–Parkinson–White syndrome.[1]
It is manufactured under the brand name Ethacizin (Этацизин) by Olainfarm.[2]
References[edit]
- ^ a b "Этацизин (Ethacyzin) Prescribing Information. VIDAL Drug Compendium" (in Russian). Retrieved 5 February 2014.
- ^ "Этацизин—4DOKTOR.RU Drug Information Handbook" (in Russian). Retrieved 5 February 2014.
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
